{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:40:05Z","timestamp":1766486405648},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Erenumab is a calcitonin gene-related peptide (CGRP)-receptor antibody inhibiting CGRP function. CGRP is prominently involved in the pathophysiology of migraine through nociceptive modulation in the trigeminovascular system. This study aims to explore the treatment effect of erenumab in a real-life setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective observational study, we analyzed the data of 91 patients with migraine receiving at least three consecutive monthly injections of erenumab and followed up for 3\u201312\u2009months. The primary objective was to describe the reduction in monthly migraine days throughout the follow-up period. To identify patients who responded to treatment, we analyzed the association between different patient characteristics and their treatment outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy-three patients (80.2%) responded to erenumab treatment, defined as \u226550% reduction of migraine days per month, across all migraine types. It was noted that ethnicity (<jats:italic>p<\/jats:italic>-value\u2009=\u20090.015) and older age (p-value\u2009=\u20090.035) were associated with clinically relevant improvement of symptoms. Middle Eastern ethnicity was related to less improvement of symptoms while Europeans were more likely to benefit from erenumab therapy (odds ratio: 12.788, <jats:italic>p<\/jats:italic>\u2009=\u20090.037). Patients aged from 31 to 40 and 41\u201365\u2009years benefited most from erenumab treatment with a response rate of 77.8 and 89.9%, respectively, also confirmed by logistic regression (<jats:italic>p<\/jats:italic>\u2009=\u20090.047). Neither gender nor dose increase of erenumab showed association with the reported clinically relevant improvement of the symptoms. An association between clinically relevant improvement of headaches and the type of migraine was also noted. Around 87.9% of patients with episodic migraine responded to treatment, followed by 84.1% of chronic migraine patients and 50% of medication overuse headache patients. Medication overuse headache showed a lower probability of therapy success with erenumab (odds ratio: 0.126, <jats:italic>p<\/jats:italic>\u2009=\u20090.039). An improvement of headaches was eminent in patients who received 140\u2009mg erenumab monthly (2\u2009\u00d7\u200970 mg injections) and patients who had one injection every two weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Erenumab is a novel preventive treatment for all migraine types. Clinically relevant improvement of headaches and reduction of monthly migraine days were demonstrated in patients that continued the treatment course. In real-life, a substantial number of patients suspended therapy early, reasons for which need further investigation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-021-02507-y","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T05:02:42Z","timestamp":1639458162000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study"],"prefix":"10.1186","volume":"21","author":[{"given":"Bui Bao Khanh","family":"Dinh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem Hamed","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Terruzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derk Wolfgang","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"2507_CR1","doi-asserted-by":"publisher","unstructured":"Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain [Internet]. 2016\/11\/14. 2016;17(1):104. https:\/\/doi.org\/10.1186\/s10194-016-0699-5. Accessed 14 Sept 2021.","DOI":"10.1186\/s10194-016-0699-5"},{"key":"2507_CR2","doi-asserted-by":"publisher","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, Headache on behalf of LTB the GC against. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain [Internet]. 2020;21(1):137. Available from: https:\/\/doi.org\/10.1186\/s10194-020-01208-0","DOI":"10.1186\/s10194-020-01208-0"},{"key":"2507_CR3","doi-asserted-by":"crossref","unstructured":"Migraine CA, Solomon CG, editor. N Engl J Med [Internet]. 2017;377(6):553\u201361. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMcp1605502","DOI":"10.1056\/NEJMcp1605502"},{"issue":"9","key":"2507_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"The International Classification of Headache Disorders","year":"2013","unstructured":"The International Classification of Headache Disorders. 3rd edition (beta version). Cephalalgia. 2013;33(9):629\u2013808.","journal-title":"Cephalalgia."},{"issue":"10","key":"2507_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","volume":"12","author":"H-C Diener","year":"2016","unstructured":"Diener H-C, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016;12(10):575\u201383.","journal-title":"Nat Rev Neurol"},{"key":"2507_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fphar.2019.00363","volume":"10","author":"D Scuteri","year":"2019","unstructured":"Scuteri D, Adornetto A, Rombol\u00e0 L, Naturale MD, Morrone LA, Bagetta G, et al. New trends in Migraine pharmacology: targeting calcitonin gene-related peptide (CGRP) with monoclonal antibodies. Front Pharmacol. 2019;10:363.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2507_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183\u20137.","journal-title":"Ann Neurol"},{"issue":"2","key":"2507_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1474-4422(17)30435-0","volume":"17","author":"A Charles","year":"2018","unstructured":"Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174\u201382.","journal-title":"Lancet Neurol"},{"issue":"11","key":"2507_CR9","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa030505","volume":"350","author":"J Olesen","year":"2004","unstructured":"Olesen J, Diener H-C, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104\u201310.","journal-title":"N Engl J Med"},{"issue":"11","key":"2507_CR10","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-019-00665-9","volume":"33","author":"C Chan","year":"2019","unstructured":"Chan C, Goadsby PJ. Recent advances in pharmacotherapy for episodic Migraine. CNS Drugs. 2019;33(11):1053\u201371.","journal-title":"CNS Drugs"},{"issue":"5","key":"2507_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11916-018-0686-4","volume":"22","author":"H Israel","year":"2018","unstructured":"Israel H, Neeb L, Reuter U. CGRP monoclonal antibodies for the preventative treatment of Migraine. Curr Pain Headache Rep. 2018;22(5):38.","journal-title":"Curr Pain Headache Rep"},{"issue":"6","key":"2507_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338\u201350.","journal-title":"Nat Rev Neurol"},{"issue":"20","key":"2507_CR13","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener H-C, Ashina M, Brandes JL, Friedman DI, Reuter U, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology. 2019;92(20):e2309\u201320.","journal-title":"Neurology."},{"issue":"6","key":"2507_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425\u201334.","journal-title":"Lancet Neurol"},{"issue":"22","key":"2507_CR15","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of Erenumab for episodic Migraine. N Engl J Med. 2017;377(22):2123\u201332.","journal-title":"N Engl J Med"},{"key":"2507_CR16","doi-asserted-by":"publisher","unstructured":"Tepper SJ, Fang J, Vo P, Shen Y, Zhou L, Abdrabboh A, et al. Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study. J Headache Pain [Internet]. 2021;22(1):27. Available from: https:\/\/doi.org\/10.1186\/s10194-021-01238-2","DOI":"10.1186\/s10194-021-01238-2"},{"key":"2507_CR17","doi-asserted-by":"publisher","unstructured":"Takahashi TT, Ornello R, Quatrosi G, Torrente A, Albanese M, Vigneri S, et al. Medication overuse and drug addiction: a narrative review from addiction perspective. J Headache Pain [Internet]. 2021;22(1):32. Available from: https:\/\/doi.org\/10.1186\/s10194-021-01224-8","DOI":"10.1186\/s10194-021-01224-8"},{"key":"2507_CR18","doi-asserted-by":"publisher","unstructured":"Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6\u2009months. J Headache Pain [Internet]. 2021;22(1):120. Available from: https:\/\/doi.org\/10.1186\/s10194-021-01328-1","DOI":"10.1186\/s10194-021-01328-1"},{"issue":"7","key":"2507_CR19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1468-2982.2008.01823.x","volume":"29","author":"HJ Maas","year":"2009","unstructured":"Maas HJ, Danhof M, Della Pasqua OE. Analysis of the relationship between age and treatment response in migraine. Cephalalgia. 2009;29(7):772\u201380.","journal-title":"Cephalalgia."},{"issue":"3","key":"2507_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2217\/pmt-2018-0030","volume":"9","author":"SM Meints","year":"2019","unstructured":"Meints SM, Cortes A, Morais CA, Edwards RR. Racial and ethnic differences in the experience and treatment of noncancer pain. Pain Manag. 2019;9(3):317\u201334.","journal-title":"Pain Manag"},{"issue":"3","key":"2507_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.pmn.2018.11.002","volume":"20","author":"M Perry","year":"2019","unstructured":"Perry M, Baumbauer K, Young EE, Dorsey SG, Taylor JY, Starkweather AR. The influence of race, ethnicity and genetic variants on postoperative pain intensity: an integrative literature review. Pain Manag Nurs Off J Am Soc Pain Manag Nurses. 2019;20(3):198\u2013206.","journal-title":"Pain Manag Nurs Off J Am Soc Pain Manag Nurses"},{"issue":"3","key":"2507_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/clpt.2013.218","volume":"95","author":"AS Kesselheim","year":"2014","unstructured":"Kesselheim AS, Gagne JJ. Strategies for postmarketing surveillance of drugs for rare diseases. Clin Pharmacol Ther. 2014;95(3):265\u20138.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02507-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02507-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02507-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T05:03:02Z","timestamp":1639458182000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02507-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2507"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02507-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"21 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the recommendations of the 18th World Health Congress (Helsinki, 1964) and all the applicable amendments, as well as the laws and regulations and any applicable guidelines of the United Arab Emirates (UAE) where the study was conducted. The study\u2019s protocol was reviewed and approved by the Dubai Healthcare City Authority \u2013 Regulatory Review Ethics Committee (DHCR Rec 2021 10 MCH Migraine). Informed consent was waived by the Dubai Healthcare City Authority \u2013 Regulatory Review Ethics Committee (DHCR Rec 2021 10 MCH Migraine) as it was not required due to the retrospective nature of the study and considering that there was no associated risk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Alessandro Terruzzi and Dr. Derk Wolfgang Krieger are on Novartis advisory board. Dr. Waseem Hamed Aziz and Bui Bao Khanh Dinh have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"486"}}